Metabolomic Profiling to Identify Potential Serum Biomarkers for Schizophrenia and Risperidone Action

Abstract

Despite recent advances in understanding the pathophysiology of schizophrenia and the mechanisms of antipsychotic drug action, the development of biomarkers for diagnosis and therapeutic monitoring in schizophrenia remains challenging. Metabolomics provides a powerful approach to discover diagnostic and therapeutic biomarkers by analyzing global changes in an individual's metabolic profile in response to pathophysiological stimuli or drug intervention. In this study, we performed gas chromatography-mass spectrometry based metabolomic profiling in serum of unmedicated schizophrenic patients before and after an 8-week risperidone monotherapy, to detect potential biomarkers associated with schizophrenia and risperidone treatment. Twenty-two marker metabolites contributing to the complete separation of schizophrenic patients from matched healthy controls were identified, with citrate, palmitic acid, myo-inositol, and allantoin exhibiting the best combined classification performance. Twenty marker metabolites contributing to the complete separation between posttreatment and pretreatment patients were identified, with myo-inositol, uric acid, and tryptophan showing the maximum combined classification performance. Metabolic pathways including energy metabolism, antioxidant defense systems, neurotransmitter metabolism, fatty acid biosynthesis, and phospholipid metabolism were found to be disturbed in schizophrenic patients and partially normalized following risperidone therapy. Further study of these metabolites may facilitate the development of noninvasive biomarkers and more efficient therapeutic strategies for schizophrenia.

UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry

“…The study revealed a disturbance in neurotransmitters and their metabolites together with 32 identified biomarkers that underpin pathways involved in neurotransmitters, amino acids, glucose, lipids, and energy metabolism, as well as antioxidant defense system, bowel microflora and endocrine system in schizophrenic patients. Bonferroni analysis of the data showed that among these metabolites pregnanediol, citrate and α-ketoglutarate were significantly associated with symptomatology of schizophrenia and may be useful biomarkers for monitoring therapeutic efficacy [111].…”

Global and Targeted Metabolomics of Esophageal Squamous Cell Carcinoma Discovers Potential Diagnostic and Therapeutic Biomarkers

“…Recently, Arun et al reported that components of the sarcosine pathway may have potential as biomarkers for prostate cancer progression and serve as new avenues for therapeutic intervention using the metabolomics approach (15). Moreover, Xuan et al used metabolomics to identify potential biomarkers associated with schizophrenia and drug treatment thereof (17). There is also a growing interest in identifying the molecular alterations associated with EC by GC-MS-and 1 H NMR-based metabolomics approach (18,19).…”

Evaluating Metabolic Responses in Mice to Nanosized Titanium Dioxide Particles Using Gas Chromatography- Mass Spectrometry Based Metabolomics

“…Quality of model is assessed on R 2 and Q 2 scores [23]. Further, model validation was performed by 500 times permutation tests [24]. Metabolites with variable importance in projection (VIP) values of greater than 1 were taken as potential marker metabolites.…”